PCM
PCRX icon

Prelude Capital Management’s Pacira BioSciences PCRX Stock Holding History

Prelude Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,000
Closed -$97K – 2103
2014
Q3 		$97K Buy
+1,000
New +$97.3K 0.01% 1102

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's PCRX Position: Q1 2026 in Review

Prelude Capital Management increased its Pacira BioSciences (PCRX) stake by 15% in Q1 2026, buying an estimated $150K and bringing the position to 50,735 shares worth $1.15M. The position accounts for 0.09% of the portfolio, ranked #274.

Prelude Capital Management first reported a position in PCRX in Q2 2014 and has held it in 26 quarters since. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Prelude Capital Management held 50,735 shares of Pacira BioSciences worth $1.15M as of Q1 2026.
  • Prelude Capital Management bought 6,740 Pacira BioSciences shares in Q1 2026, an estimated $150K.
  • Pacira BioSciences made up 0.09% of Prelude Capital Management's portfolio in Q1 2026, its #274 holding.
  • Prelude Capital Management first reported a position in Pacira BioSciences in Q2 2014 and has held it in 26 quarters since.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.